Testosterone and Fertility
Between 2007 and 2011, one research group in the north Indian city of Lucknow published four papers that are still, more than a decade later, the entire human evidence base for using Mucuna pruriens as a fertility treatment.
The protocol was the same each time and it was very simple: 5 g a day of powdered Mucuna pruriens seed, taken by mouth, for three months. The men who took it were being investigated for infertility. Before treatment and again at three months, the researchers measured semen and drew blood.
What they reported is genuinely interesting. Testosterone and luteinizing hormone (LH) went up. Prolactin and follicle-stimulating hormone (FSH) came down. Sperm count and motility improved. The antioxidant enzymes in seminal fluid — superoxide dismutase and catalase — which had been running low, came back up. Lipid peroxide, the marker of oxidative damage, came down. A separate study used nuclear magnetic resonance (NMR) spectroscopy to look at the small-molecule chemistry of seminal plasma and found several metabolites shifting back toward the values seen in fertile men.
And here is the sentence that has to sit next to all of that, because the supplement industry has spent fifteen years leaving it out: every one of those men was infertile. In one of the studies they were also under measurable psychological stress, with raised cortisol to prove it. Nobody in these trials was a healthy fertile man taking Mucuna to feel stronger in the gym. The evidence is about correcting a deficit, not about pushing a normal system higher, and those are not the same claim.
This article walks through what was measured, why the dopamine–prolactin link makes the hormone result mechanistically sensible rather than mysterious, where the study designs are weak, what the animal work adds, and the specific pharmacology cautions — some of which are serious — that come with a bean that is roughly 4–7% levodopa by weight.
Table of Contents
- The Lucknow Studies: What Was Actually Done
- The Hormone Results: Testosterone, Luteinizing Hormone, Follicle-Stimulating Hormone and Prolactin
- Why Dopamine Lowers Prolactin, and Why That Lifts Testosterone
- Sperm Count and Motility: What “Improved” Meant
- The Oxidative-Stress Arm: Superoxide Dismutase, Catalase, Glutathione, Vitamin C
- What NMR Found in Seminal Plasma
- The Stressed Subgroup and Cortisol
- Why This Is Not Evidence for a “Testosterone Booster”
- The Honest Limits of This Evidence
- What the Animal Work Adds — and Does Not
- Dosing, Forms and Standardisation
- Cautions: Drugs, Psychiatry and the Itching Hairs
- Who the Studies Covered and Who They Did Not
- Key Research Papers
- Connections
- Featured Videos
The Lucknow Studies: What Was Actually Done
Four papers, one group, one intervention. It helps to see them laid out, because press coverage tends to blur them into a single “study” that sounds much larger than any of them is.
- Ahmad and colleagues, Fertility and Sterility, 2008. Sixty men undergoing infertility screening, plus sixty healthy fertile men as a reference group. The focus was the biochemistry of seminal plasma — lipids, lipid peroxide, fructose, and vitamins A, C and E, measured by high-performance liquid chromatography (HPLC) and standard spectrophotometry (PMID 18001713).
- Shukla and colleagues, Evidence-Based Complementary and Alternative Medicine, 2010 (published online 2007). Sixty infertile men who were also under psychological stress — identified by questionnaire and by raised serum cortisol — plus sixty age-matched fertile controls. This is the paper that states the dose in plain text: 5 g per day of seed powder, three months. Its focus was the antioxidant defence system (PMID 18955292).
- Shukla and colleagues, Fertility and Sterility, 2009. Seventy-five infertile men, seventy-five fertile controls. This is the hormone paper: testosterone, luteinizing hormone, follicle-stimulating hormone and prolactin by radioimmunoassay, plus dopa, adrenaline and noradrenaline measured by HPLC in both blood and seminal plasma (PMID 18973898).
- Gupta and colleagues, Journal of Pharmaceutical and Biomedical Analysis, 2011. The largest of the four: 180 infertile men treated for three months, with fifty age-matched healthy men as controls. Proton NMR spectroscopy of seminal plasma metabolites, alongside repeat semen analysis and the same four hormones (PMID 21459537).
Two design facts matter enormously and are almost never mentioned when these results are quoted.
First, there was no placebo group. The abstracts describe these as prospective studies. The healthy fertile men were a reference group — a yardstick for what normal looks like — not a control arm swallowing a matched dummy powder. The actual comparison in every paper is each infertile man against his own baseline three months earlier. That is a legitimate way to generate a hypothesis. It is not a way to prove a treatment works, because it cannot separate the drug from regression to the mean, from seasonal and biological variability in semen quality (which is large), or from the well-documented tendency of people in a study to change other things about their lives at the same time.
Second, all four papers come from one group at one institution, with an overlapping author list. Independent replication elsewhere has not happened. In the fifteen years since, the searchable literature on Mucuna pruriens and human semen has not grown much: a PubMed query for the plant crossed with human semen returns fewer than a dozen records, and most of those are reviews summarising these same four studies, animal work, or papers about entirely different plants. When you read a supplement page citing “multiple clinical studies”, this is what it means.
The Hormone Results: Testosterone, Luteinizing Hormone, Follicle-Stimulating Hormone and Prolactin
The 2009 paper is the one everybody is really quoting. Its finding, in the authors' own summary, was that infertile men started with lower testosterone and luteinizing hormone, and lower dopamine, adrenaline and noradrenaline in both blood and seminal plasma, than fertile controls. Men in the oligozoospermic group (low sperm count) additionally showed raised follicle-stimulating hormone and raised prolactin.
After three months of Mucuna pruriens:
- Testosterone rose significantly.
- Luteinizing hormone rose significantly.
- Follicle-stimulating hormone fell.
- Prolactin fell.
- Dopamine, adrenaline and noradrenaline all rose in blood and in seminal plasma.
- Sperm count and motility recovered significantly.
The authors' conclusion was that the plant “regulates steroidogenesis and improves semen quality in infertile men”.
Note what direction each hormone moved, because it is not random and it is not what a crude “this raises testosterone” story predicts. If Mucuna were simply acting as an androgen — an exogenous testosterone-like substance — then luteinizing hormone would have gone down, suppressed by negative feedback, and follicle-stimulating hormone with it, and sperm production would have fallen. That is exactly what happens to men who take testosterone: their own axis switches off and their sperm count often drops to zero. Instead luteinizing hormone went up while testosterone went up, which is the signature of the pituitary being released, not bypassed.
The falling follicle-stimulating hormone is the mirror image of the same logic. Follicle-stimulating hormone is high in men with failing sperm production because the testis is not sending back enough inhibin B to shut it off; as spermatogenesis recovers, follicle-stimulating hormone comes down. A drop in follicle-stimulating hormone here is a sign of the testis working better, not worse.
That internal consistency is the strongest argument the Lucknow data has. Uncontrolled before-and-after studies produce noise all the time — but noise does not usually arrange itself into a coherent endocrine pattern across four separate hormones.
Why Dopamine Lowers Prolactin, and Why That Lifts Testosterone
Here is the mechanism, in the order it happens.
Step one: the bean is levodopa. Mucuna pruriens seed contains L-DOPA — the identical molecule to prescription levodopa — at a few percent of its dry weight. This is not a metaphor or an “L-DOPA-like compound”. It is the drug, in a bean. Everything else on this page follows from that one fact.
The same molecule does not mean the same blood level. Small pharmacokinetic studies in Parkinson's disease have compared Mucuna directly against standard levodopa tablets, which pair levodopa with a decarboxylase inhibitor (carbidopa or benserazide). In two patients, levodopa bioavailability was “markedly lower” after Mucuna: 100 mg of levodopa from Mucuna capsules gave a peak blood level of 1.0 mg/L, against 2.0 mg/L from 100 mg of levodopa with 25 mg carbidopa, and the area under the blood-level curve fell from 137 to 33.6 mg/L per minute; the authors explain this by the missing decarboxylase inhibitor (PMID 26366963). In four patients, a similar levodopa dose from Mucuna gave less clinical benefit and a 3.5-fold lower median area under the curve than levodopa with a decarboxylase inhibitor (PMID 27206902).
Step two: L-DOPA becomes dopamine. L-DOPA crosses into the brain and is decarboxylated to dopamine. In the hypothalamus, that matters for a specific reason.
Step three: dopamine is the brake on prolactin. Almost every hormone in the body is controlled by a releasing signal from the hypothalamus. Prolactin is the exception — it is controlled by an inhibiting signal. Neurons in the arcuate nucleus release dopamine into the pituitary portal circulation, and that dopamine continuously tells the lactotroph cells of the anterior pituitary not to secrete prolactin. Take the dopamine away and prolactin rises immediately. This is why drugs that block dopamine receptors — most antipsychotics, and the anti-nausea drug metoclopramide — reliably cause high prolactin as a side effect, and why the treatment for a prolactin-secreting pituitary tumour is a dopamine agonist such as cabergoline (PMID 36974474).
Step four: prolactin suppresses the testosterone axis. Sustained high prolactin blunts the pulsatile release of gonadotropin-releasing hormone (GnRH) from the hypothalamus. Fewer GnRH pulses means less luteinizing hormone from the pituitary, and luteinizing hormone is the signal that tells the Leydig cells of the testis to make testosterone. The clinical picture of hyperprolactinaemia in men is therefore low testosterone, low libido, erectile difficulty and impaired sperm production — and correcting the prolactin with a dopamine agonist restores the axis.
Put the four steps together and the Lucknow hormone result stops being surprising:
L-DOPA → more dopamine → less prolactin → GnRH pulses recover → luteinizing hormone rises → testosterone rises.
And it explains the crucial caveat at the same time. Releasing a brake only helps if the brake was on. In men whose prolactin is already normal, there is no suppression to relieve. The mechanism predicts, of itself, that the men who benefit are the ones with a dopamine deficit or a prolactin excess — which is exactly the population studied, and exactly not the population buying the supplement.
The 2009 paper supports the first half of that chain directly: it measured dopamine in blood and seminal plasma, found it low in infertile men to begin with, and found it rising with treatment. That is an unusual and useful piece of data. It means the study did not merely assume the mechanism; it observed the intermediate step.
Sperm Count and Motility: What “Improved” Meant
All four papers report improvement in sperm concentration and motility. The 2008 Fertility and Sterility paper is the one that is most specific about who improved and by how much — and it contains the single most useful sentence in the entire series, because it is a negative one.
In the authors' own words, treatment increased sperm concentration and motility in all the infertile groups; oligozoospermic patients recovered sperm concentration significantly, but sperm motility was not restored to normal levels in asthenozoospermic men.
Unpack that:
- Oligozoospermia means too few sperm. In this group, the count came up meaningfully.
- Asthenozoospermia means enough sperm, but too few of them swimming properly. In this group, motility improved — but it did not reach the normal range.
That is a real and specific limit, published by the researchers themselves in the abstract, and it is exactly the kind of detail that gets stripped out when a result is repackaged as marketing copy. If your semen analysis shows a motility problem rather than a count problem, the strongest reading of this evidence is “may help, unlikely to fix it”.
A second caution on the numbers, which applies to every uncontrolled semen study and not just this one: semen parameters are enormously variable within the same man. Count and motility swing with fever, illness, abstinence interval, season, sleep and time of day. A single baseline sample followed by a single three-month sample, with no placebo arm, is a design in which some improvement is expected by chance alone — men are usually enrolled when their numbers are bad, and bad numbers tend to drift back toward that man's own average whether or not anything is done. This does not mean the effect is fake. It means the study cannot tell you how much of it was the bean.
The Oxidative-Stress Arm: Superoxide Dismutase, Catalase, Glutathione, Vitamin C
Sperm are unusually vulnerable to oxidative damage, and the reason is structural. Their membranes are exceptionally rich in polyunsaturated fatty acids, which is what makes the tail flexible enough to swim — and polyunsaturated fats are precisely what free radicals attack. A sperm cell also carries very little cytoplasm, and cytoplasm is where a cell keeps most of its antioxidant machinery. So a sperm is a fragile, fat-rich cell with the protective equipment stripped out, and it depends on the surrounding seminal plasma to do the defending for it.
Both the 2008 and the 2010 papers went after this directly, and both found the defence system depleted in infertile men before treatment and improved afterwards.
From the 2010 stress paper (PMID 18955292), the men had, at baseline:
- Raised seminal plasma lipid peroxide — the chemical residue of membrane fat being oxidised. This is damage that has already happened.
- Reduced superoxide dismutase (SOD) and reduced catalase activity. These are the two front-line enzymes: superoxide dismutase converts superoxide into hydrogen peroxide, and catalase converts hydrogen peroxide into water. They work in sequence, and both were down.
- Reduced glutathione and reduced ascorbic acid (vitamin C).
After three months on 5 g/day, lipid peroxide fell and superoxide dismutase, catalase, glutathione and ascorbic acid were all restored, alongside the improvement in count and motility.
The 2008 paper adds the fat-soluble side of the same story: lipid peroxidation was inhibited, and the levels of vitamins A, C and E in seminal plasma recovered, as did total lipids, triglycerides, cholesterol and phospholipids. It also reported that fructose was corrected — a detail worth a sentence, because seminal fructose is made by the seminal vesicles under androgen control and is the main fuel sperm burn to swim. Fructose being abnormal, and then normalising, is consistent with the androgen picture improving.
How much of this is Mucuna acting as an antioxidant in its own right, and how much is downstream of hormones recovering? The studies cannot separate the two. Both are plausible, and the plant does have measurable antioxidant activity in the laboratory. But note the sequencing problem: a herb that merely mopped up free radicals would not be expected to move luteinizing hormone and prolactin. A herb that restored the hormonal axis would be expected to improve seminal antioxidant status as a consequence. The parsimonious reading is that the dopamine effect is primary and the antioxidant findings largely follow it — though that is an inference, not something the data proves.
What NMR Found in Seminal Plasma
The 2011 paper (PMID 21459537) is the most technically ambitious of the four and, at 180 treated men, the largest. Rather than measuring a short list of pre-chosen chemicals, it used proton nuclear magnetic resonance spectroscopy to profile seminal plasma broadly — a method that reads many small molecules at once from a single sample.
The metabolites tracked were lactate, alanine, choline, citrate, glycerophosphocholine, glutamine, tyrosine, histidine, phenylalanine and uridine. After three months of treatment, the authors reported that Mucuna rectified the disturbed levels of alanine, citrate, glycerophosphocholine, histidine and phenylalanine, moving them toward the profile seen in the fifty healthy control men, with concurrent improvement in the clinical semen variables and the reproductive hormones.
Two of those are worth knowing about:
- Citrate is overwhelmingly a prostate product, and its secretion is androgen-dependent. Citrate normalising is another independent hint that androgen signalling improved — a different tissue telling the same story as the blood testosterone.
- Glycerophosphocholine comes chiefly from the epididymis, the coiled tube where sperm mature and acquire the ability to swim. It is used as a marker of epididymal function, so a shift there points to something happening beyond the testis itself.
The same group had earlier published the methodological groundwork for reading these spectra — a discriminant-function model that classified seminal plasma samples by their NMR profile (PMID 20719458). That is a reasonable piece of technique, and it is fair to say the analytical side of this work is more sophisticated than the trial design side.
Read for what it is, it remains a description of chemistry moving in a favourable direction in an uncontrolled cohort. Metabolite normalisation is a biomarker, not a baby. None of the four papers reports pregnancy rates or live births, which is the outcome that actually matters to a couple trying to conceive. Fifteen years on, nobody has run that trial.
The Stressed Subgroup and Cortisol
The 2010 paper deliberately narrowed its population: not just infertile men, but infertile men under psychological stress, identified both by questionnaire and by an objectively elevated serum cortisol. Sixty of them, against sixty age-matched fertile controls.
This is a real clinical group rather than a contrived one. Chronic stress suppresses male fertility through several converging routes — cortisol interferes with GnRH pulsatility, glucocorticoids act directly on Leydig cells to reduce testosterone output, and the resulting oxidative burden lands on precisely the fragile cells described above. Infertility itself is also a potent source of stress, so the arrow runs in both directions and a feedback loop is easy to fall into.
After three months of 5 g/day, the authors reported that treatment “significantly ameliorated psychological stress” along with the fall in seminal lipid peroxide, the restoration of superoxide dismutase, catalase, glutathione and ascorbic acid, and the improvement in sperm count and motility. Their conclusion was that Mucuna both reactivates the antioxidant defence system and helps in the management of stress.
Mechanistically this is coherent with the dopamine story rather than being a separate claim. Dopaminergic tone modulates the hypothalamic–pituitary–adrenal axis, so a levodopa-containing seed nudging both the reproductive and the stress axes at once is not two effects but one input with two outputs. The companion article on stress and cortisol covers that side in more depth.
The caveats are the same as everywhere else on this page: no placebo, and a stress questionnaire administered by researchers who knew every participant was receiving the treatment is about as suggestible an outcome measure as exists. Self-reported stress improving in an unblinded study is close to uninformative on its own. The cortisol and the antioxidant enzymes are harder to talk yourself into.
Why This Is Not Evidence for a “Testosterone Booster”
Mucuna is sold hard to men who want more testosterone for training, body composition, energy and libido. The Lucknow data is the evidence those adverts lean on. It does not support them, and the reasons are worth stating plainly.
- The wrong population. Every participant was an infertile man, screened at a fertility clinic; in the 2010 study they were additionally selected for measurable stress and high cortisol. Every one of them started with testosterone, luteinizing hormone and dopamine below the fertile controls. A study in men with a deficit tells you about correcting a deficit. It cannot tell you what happens to a man whose numbers are already normal, because no such man was enrolled.
- The mechanism itself predicts a ceiling. Mucuna raises testosterone by removing an inhibition — lifting prolactin's suppression of GnRH. If prolactin is not elevated and dopamine tone is not low, there is nothing to release. This is not a hostile interpretation; it is what the pathway implies, and it is why the effect and the population fit together so neatly.
- The positive review data are about men with a deficit. A broad 2019 review of plant products for testosterone, sperm and prostate parameters found that tribulus and maca were “not scientifically supported” for raising testosterone in men, rated the evidence for Mucuna as moderate, and concluded that “scientific evidence supports the use of mucuna and ashwagandha” for improving serum testosterone and semen parameters (PMID 30790614). The numbers behind that conclusion come from men with a low sperm count (oligozoospermia): the review summarised an increase in total testosterone of 151 ng/dL and an increase in sperm count of 83.3 million/mL after 5000 mg/d of powdered mucuna seed over 12 weeks. Its abstract draws no conclusion about healthy men.
- No healthy-volunteer trial exists. Not a positive one, not a negative one. A product page that claims Mucuna raises testosterone in healthy men has no study of healthy men behind it.
- “It felt like it worked” is dopamine, not androgen. A levodopa-containing seed produces noticeable subjective effects — drive, motivation, mood, libido — within hours, long before any hormone could plausibly have changed. Those effects are real, but they are the dopamine talking. Interpreting them as a testosterone rise is a very easy mistake to make and it feeds a great many five-star reviews.
Two reviews of medicinal plants for male infertility include Mucuna. A 2021 systematic review admitted only randomized placebo-controlled trials and found that all but one of its 20 trials (1519 people, eleven plants) confirmed benefits on sperm and reproductive measures (PMID 34721595). Its one Mucuna entry is the 2009 Lucknow hormone paper, which the review's table lists as placebo-controlled, while that paper's own abstract describes a prospective study with fertile men as the comparison group (PMID 18973898). A 2020 narrative review lists Mucuna among the plants with effects on the male gonads and notes that efforts to apply such plants at the clinical level “have been limited” (PMID 31989693). “Promising in infertile men” and “effective in healthy men” are separated by a study nobody has run.
The Honest Limits of This Evidence
Collected in one place, so they can be weighed together rather than met one at a time:
- No placebo control in any of the four studies. The comparison is before-versus-after within the treated men. Fertile controls were a reference standard, not a randomised arm.
- No randomisation and no blinding. Everyone knew who was taking what.
- One centre, one group, overlapping authors, one 2007–2011 window. Four papers from a single laboratory are not four independent confirmations.
- No replication in fifteen years. Nobody in another country has repeated this. For a cheap, freely available, non-patentable intervention, that is disappointing but not surprising — there is nobody with a commercial reason to fund the trial.
- No fertility outcomes. No pregnancies, no live births. Semen parameters are a proxy, and a loose one: men with poor numbers father children and men with excellent numbers sometimes do not.
- Seed powder was not standardised for L-DOPA content. L-DOPA varies substantially between cultivars, growing conditions, processing and storage, and it degrades on exposure to heat and light. Two 5 g doses from different sources are not necessarily the same dose of the active compound.
- Semen parameters are intrinsically noisy, and men are typically enrolled when their results are at their worst — a setup that manufactures apparent improvement in any uncontrolled study.
- The self-reported stress measure was unblinded and carries little weight; the cortisol and enzyme measurements carry more.
What survives all of that? Something worth taking seriously but not worth overstating: a coherent, mechanistically explicable set of changes across hormones, antioxidant enzymes and seminal metabolites, in the right direction, in a population where the mechanism predicts a benefit, reported by one group and never independently confirmed. That evidence covers men undergoing infertility screening. It does not cover fertile men with normal hormones who would like more testosterone.
What the Animal Work Adds — and Does Not
The animal literature is larger, better controlled, and about animals. Read in that spirit, it does two useful things: it supplies control groups the human work lacks, and it identifies which component of the seed is doing the work.
The mechanism study. Singh and colleagues (2013) used ethinyl oestradiol (3 mg/kg body weight daily for 14 days) to deliberately wreck spermatogenesis in rats, then gave either whole Mucuna pruriens or isolated L-DOPA for 56 days, comparing both against a group left to recover on its own. Both treated groups recovered faster and more completely than the auto-recovery group, with lower reactive oxygen species, restored mitochondrial membrane potential, regulated apoptosis, a recovered hypothalamic–pituitary–gonadal axis, more testicular germ cells, and higher sperm count and motility. The authors stated it was the first study to demonstrate that L-DOPA largely accounts for the pro-spermatogenic properties of the plant (PMID 23349947).
That is an important result for a practical reason. If the active principle is L-DOPA, then Mucuna's fertility effect is not a mysterious synergy of an Ayurvedic whole plant — it is a drug effect, with a drug's dose-response and a drug's interactions. The cautions section below follows directly from it.
The chronic-stress model. A 2022 study gave rats aqueous Mucuna pruriens seed extract at 150 or 300 mg/kg for 20 days before, and then alongside, 81 days of induced chronic stress (immobilisation and forced swimming). Pre-treated animals had lower cortisol and better protected testicular and epididymal tissue, with improved sperm count, viability and acrosome integrity, improved expression of the steroidogenic proteins StAR and CYP11A1 and of the androgen receptor, and reduced caspase activity. The abstract reports, for the extract-treated rats, a cortisol level of 0.84 µg/dL, a sperm count of 49.78 million/mL and sperm viability of 90.01% (PMID 35180038). This is the animal analogue of the 2010 human stress study, with the controls that study did not have.
The ageing model. In 24-month-old rats given seed extract at 200 mg/kg for 60 days, total and free testosterone, follicle-stimulating hormone and luteinizing hormone all rose, and testicular architecture improved measurably against untreated aged animals — tubular diameter up about 25%, number of tubules about 35%, epithelial height about 25%, epithelial volume about 20%, and Leydig cell number about 35% — with inflammatory and apoptotic markers reduced (PMID 37229277).
The livestock study. Twenty-four rabbit bucks were fed diets containing 0, 1.5 or 3% Mucuna seed meal for three months. At 3%, sperm motility rose about 36% and concentration about 66% against controls, morphological abnormalities fell about 68%, and mating behaviour changed measurably — mounting latency down about 70%, successful mounting frequency up about 60% (PMID 30659457).
Taken together the animal work is consistent, dose-responsive and mechanistically detailed. It is also, in every case, an animal given an extract at a dose calculated per kilogram of body weight, usually in a model of deliberately induced damage. None of it establishes an effect in a healthy human, and per-kilogram animal doses do not translate directly to human ones.
Dosing, Forms and Standardisation
What the human studies used, exactly:
- Form: powdered Mucuna pruriens seed. Not a standardised extract, not an L-DOPA concentrate — ground whole seed.
- Dose: 5 g per day, orally.
- Duration: three months. Every one of the four papers ran for three months, and there is a biological reason that is the right minimum: a full cycle of human spermatogenesis takes roughly 64 days, plus a further two weeks or so for transit and maturation through the epididymis. Nothing you do to sperm production shows up in a semen analysis in less than about ten weeks. A one-month trial of anything for male fertility is a wasted month.
Some practical points that follow.
Five grams of seed powder is a lot of powder. It is a heaped teaspoon or more, not a capsule. Most capsules on the market hold 300–500 mg of extract, so a product sold as “Mucuna” may deliver a small fraction of the studied dose — or, if it is a 15–99% L-DOPA extract, several times more of the active compound in a much smaller pill. These are not interchangeable, and the label rarely makes the difference obvious.
Standardised extracts are a different product. Whole seed powder is roughly 4–7% L-DOPA depending on cultivar and processing, so 5 g of powder supplies a couple of hundred milligrams of L-DOPA spread across a food matrix. A “99% L-DOPA” extract is, functionally, unregulated levodopa. The Parkinson's pharmacokinetic literature adds a twist: measured against standard levodopa tablets that contain a decarboxylase inhibitor, Mucuna preparations gave markedly lower blood levels of levodopa at a similar dose, and the 2016 authors concluded that Mucuna may provide clinical benefit only when its levodopa content is at least 3.5-fold the standard dose given with a decarboxylase inhibitor (PMID 26366963, PMID 27206902).
L-DOPA content is unstable and unlabelled. It varies with variety, soil, harvest and storage, and it degrades with heat, light and time. Cassani and colleagues had to measure L-DOPA content directly when working out a low-cost preparation method for Parkinson's patients, precisely because you cannot assume it from the weight of powder (PMID 27206902). Across 25 seed samples from Africa, Latin America and Asia, they found a median levodopa content of 5.29% in dried seed and 5.3% in roasted powder, while boiling reduced the levodopa content by up to 70% — so how the bean is prepared changes the dose a great deal (PMID 27206902). Nothing on a supplement label tells you what you are actually getting.
Timing and food. L-DOPA competes with dietary amino acids for the same intestinal and blood–brain-barrier transporters, so a large protein meal blunts absorption. Between meals is more consistent. Nausea is the commonest complaint and is usually dose-related.
Cautions: Drugs, Psychiatry and the Itching Hairs
This is the section that matters most, and it exists because of one fact established earlier: the active compound is a prescription drug. The warnings on the levodopa label apply here, with the added problem that the dose is unknown.
Drug combinations the levodopa label warns about
- Prescription levodopa or carbidopa–levodopa. Taking Mucuna on top is dose-stacking the same molecule. In Parkinson's disease some people do use Mucuna deliberately — the two patients in the 2015 kinetic study were taking standard levodopa together with self-prescribed Mucuna, and the pharmacokinetic studies above exist for exactly that reason. Uncontrolled stacking risks dyskinesia, nausea, hallucinations and blood-pressure swings.
- MAO inhibitors. Non-selective monoamine oxidase inhibitors (phenelzine, tranylcypromine, isocarboxazid) with a levodopa source is a classic and dangerous combination — a hypertensive crisis is the recognised risk. Linezolid, an antibiotic, is also a monoamine oxidase inhibitor and is easy to overlook. The carbidopa-levodopa label lists non-selective monoamine oxidase inhibitors as a contraindication and states that they are stopped at least two weeks before the drug is started.
- Antipsychotics and other dopamine antagonists. Two problems at once, pulling opposite ways. Mucuna undermines what the antipsychotic is doing, and the antipsychotic blocks Mucuna's mechanism. The same applies to metoclopramide and prochlorperazine for nausea. The carbidopa-levodopa label states that dopamine D2 receptor antagonists (for example phenothiazines, butyrophenones and risperidone) may reduce the effects of levodopa, and that metoclopramide may worsen disease control through its dopamine-blocking action.
- Antihypertensives. Levodopa can lower blood pressure and cause orthostatic drops — the light-headedness on standing that leads to falls.
- Antidepressants and other serotonergic drugs. The carbidopa-levodopa label does not list selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) or triptans among its drug interactions. It does report rare cases of high blood pressure and dyskinesia when carbidopa-levodopa was combined with tricyclic antidepressants.
Psychiatric risk is real at high dose
The most sobering entry in this plant's literature is a 1990 report in The Lancet of an outbreak of acute toxic psychosis attributed to Mucuna pruriens (PMID 1978001). It was a food-exposure setting rather than a supplement one, and the report is brief, but it establishes the point that matters: a levodopa-rich food can produce psychosis at sufficient exposure. Dopaminergic drugs are known to cause hallucinations, agitation, confusion and impulse-control problems, and none of that becomes impossible because the source is a bean.
The concern is greatest for people with a history of psychosis, schizophrenia, bipolar disorder or a serious impulse-control problem. The carbidopa-levodopa label advises that patients with a major psychotic disorder ordinarily are not treated with the drug, because of the risk of making the psychosis worse, and it describes intense urges to gamble, spend money, binge-eat or for sex in people taking dopaminergic medicines. For everyone else, escalating the dose carries a real downside, not just a lack of effect.
The hairs on the pod are a genuine hazard
The species name pruriens is Latin for “itching”, and it was not chosen casually. The seed pods are covered in fine barbed spicules containing a protease that produces intense, prolonged, maddening itching on skin contact — the plant's common English name in parts of the world is cowitch, and it has been used as an itching powder. In the eye it can cause a serious inflammatory reaction. The properly processed seed powder sold as a supplement does not contain these hairs, but raw pods cause the reaction through skin and eye contact, and the spicules become airborne.
Other cautions
- Pregnancy and breastfeeding. Levodopa suppresses prolactin, which is the hormone lactation depends on, and levodopa has been detected in human milk; the carbidopa-levodopa label reports no adequate or well-controlled studies in pregnant women. For Mucuna itself, safety data is absent.
- Melanoma. Levodopa is a precursor of melanin as well as dopamine, and the labelling for prescription levodopa carries a caution in patients with melanoma or undiagnosed suspicious skin lesions. That caution transfers.
- Surgery and anaesthesia. Interactions with anaesthetic agents and with the dopamine antagonists used for post-operative nausea are the concern.
- Diagnosis. Male infertility has causes — varicocele, obstruction, infection, genetic conditions such as Klinefelter syndrome or Y-chromosome microdeletion, thyroid disease, and pituitary tumours that raise prolactin. That last one is worth dwelling on, because Mucuna would partially mask a prolactinoma by pushing prolactin down without treating the tumour. A semen analysis, a hormone panel including prolactin, and a urology or reproductive endocrinology assessment are how these causes are told apart.
- Suspected low testosterone. Fatigue and low libido have many causes, several of them serious. A morning testosterone measurement is the test that confirms or rules out low testosterone.
Who the Studies Covered and Who They Did Not
Pulling it together.
The studied men were being investigated for infertility, with low sperm count, low testosterone, low luteinizing hormone or a raised prolactin. For that group the seed is inexpensive, the mechanism fits, and the human data, weak as its design is, comes from that population. The studies used 5 g/day of seed powder for three months and re-tested semen and blood at the end. Because Mucuna moves prolactin, it also changes how hormone results are read.
For fertile men with normal prolactin and normal testosterone, the evidence on this page does not apply. A dopaminergic lift in drive and mood may still be noticeable — that effect is real and is covered in the dopamine and mood article — but it is not a testosterone effect, and no study has tested Mucuna as a testosterone booster in men whose testosterone is normal.
For people taking an antipsychotic, a monoamine oxidase inhibitor or prescription levodopa, the interactions in the cautions section above apply — the levodopa label lists non-selective monoamine oxidase inhibitors as a contraindication.
Other factors in male fertility include smoking, scrotal heat, a varicocele, a genuine zinc or selenium deficiency, sleep, and the stress that the 2010 study was built around.
Key Research Papers
Every citation below has been checked against its PubMed record. Where a claim on this page rests on a number, that number appears in the abstract of the paper cited beside it.
- Ahmad MK, Mahdi AA, Shukla KK, Islam N, Jaiswar SP, Ahmad S. Effect of Mucuna pruriens on semen profile and biochemical parameters in seminal plasma of infertile men. Fertility and Sterility. 2008;90(3):627–635. — PubMed PMID: 18001713
- Shukla KK, Mahdi AA, Ahmad MK, Shankhwar SN, Rajender S, Jaiswar SP. Mucuna pruriens improves male fertility by its action on the hypothalamus-pituitary-gonadal axis. Fertility and Sterility. 2009;92(6):1934–1940. — PubMed PMID: 18973898
- Shukla KK, Mahdi AA, Ahmad MK, Jaiswar SP, Shankwar SN, Tiwari SC. Mucuna pruriens reduces stress and improves the quality of semen in infertile men. Evidence-Based Complementary and Alternative Medicine. 2010;7(1):137–144. — PubMed PMID: 18955292
- Gupta A, Mahdi AA, Ahmad MK, Shukla KK, Bansal N, Jaiswer SP, Shankhwar SN. A proton NMR study of the effect of Mucuna pruriens on seminal plasma metabolites of infertile males. Journal of Pharmaceutical and Biomedical Analysis. 2011;55(5):1060–1066. — PubMed PMID: 21459537
- Gupta A, Mahdi AA, Ahmad MK, Shukla KK, Jaiswer SP, Shankhwar SN. 1H NMR spectroscopic studies on human seminal plasma: a probative discriminant function analysis classification model. Journal of Pharmaceutical and Biomedical Analysis. 2011;54(1):106–113. — PubMed PMID: 20719458
- Singh AP, Sarkar S, Tripathi M, Rajender S. Mucuna pruriens and its major constituent L-DOPA recover spermatogenic loss by combating ROS, loss of mitochondrial membrane potential and apoptosis. PLoS One. 2013;8(1):e54655. — PubMed PMID: 23349947
- Lapyuneyong N, Tangsrisakda N, Choowong-In P, Chaisiwamongkol K, Uabundit N, Sawatpanich T, Arun S, Wu AT, Iamsaard S. Seed extract of Thai Mucuna pruriens reduced male reproductive damage in rats induced by chronic stress. Pharmaceutical Biology. 2022;60(1):374–383. — PubMed PMID: 35180038
- Ganesh MK, Lakshmanan G, Khan MZI, Prakash S. Aging induced testicular damage: analyzing the ameliorative potential of Mucuna pruriens seed extract. 3 Biotech. 2023;13(6):206. — PubMed PMID: 37229277
- Mutwedu VB, Ayagirwe RBB, Bacigale SB, Mwema LM, Butseme S, Kashosi T, Mitima B, Manyawu GJ, Nyongesa AW. Effect of dietary inclusion of small quantities of Mucuna pruriens seed meal on sexual behavior, semen characteristics, and biochemical parameters in rabbit bucks (Oryctolagus cuniculus). Tropical Animal Health and Production. 2019;51(5):1195–1202. — PubMed PMID: 30659457
- Santos HO, Howell S, Teixeira FJ. Beyond tribulus (Tribulus terrestris L.): the effects of phytotherapics on testosterone, sperm and prostate parameters. Journal of Ethnopharmacology. 2019;235:392–405. — PubMed PMID: 30790614
- Roozbeh N, Amirian A, Abdi F, Haghdoost S. A systematic review on use of medicinal plants for male infertility treatment. Journal of Family and Reproductive Health. 2021;15(2):74–81. — PubMed PMID: 34721595
- Abarikwu SO, Onuah CL, Singh SK. Plants in the management of male infertility. Andrologia. 2020;52(3):e13509. — PubMed PMID: 31989693
- Infante ME, Perez AM, Simao MR, Manda F, Baquete EF, Fernandes AM, Cliff JL. Outbreak of acute toxic psychosis attributed to Mucuna pruriens. The Lancet. 1990;336(8723):1129. — PubMed PMID: 1978001
- Contin M, Lopane G, Passini A, Poli F, Iannello C, Guarino M. Mucuna pruriens in Parkinson disease: a kinetic-dynamic comparison with levodopa standard formulations. Clinical Neuropharmacology. 2015;38(5):201–203. — PubMed PMID: 26366963
- Cassani E, Cilia R, Laguna J, Barichella M, Contin M, Cereda E, Isaias IU, Sparvoli F, Akpalu A, Budu KO, Scarpa MT, Pezzoli G. Mucuna pruriens for Parkinson's disease: low-cost preparation method, laboratory measures and pharmacokinetics profile. Journal of the Neurological Sciences. 2016;365:175–180. — PubMed PMID: 27206902
- Lampariello LR, Cortelazzo A, Guerranti R, Sticozzi C, Valacchi G. The magic velvet bean of Mucuna pruriens. Journal of Traditional and Complementary Medicine. 2012;2(4):331–339. — PubMed PMID: 24716148
- Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R. Approach to the patient with prolactinoma. The Journal of Clinical Endocrinology & Metabolism. 2023;108(9):2400–2423. — PubMed PMID: 36974474
PubMed Topic Searches
Connections
- Mucuna Pruriens (Velvet Bean) — the main topic page: botany, traditional use, chemistry and the full picture of what this seed does.
- Mucuna Pruriens — Benefits Deep Dive — the hub that maps all four benefit areas and labels how strong the evidence is for each.
- Dopamine and Mood — the subjective drive-and-motivation effect that is easily mistaken for a testosterone rise.
- Stress and Cortisol — the hypothalamic-pituitary-adrenal-axis side of the same 2010 study population.
- Testosterone Test: Total, Free and Bioavailable — how to actually measure the hormone before assuming it is low.
- Ashwagandha (Withania somnifera) — the other adaptogen studied by the same Lucknow group for male fertility, with a different mechanism.
- Tribulus terrestris — the best-known herbal “testosterone booster”, and a useful comparison for how thin that category's evidence is.
- Zinc — essential for spermatogenesis and testosterone synthesis; correcting a real deficiency matters more than any herb.
- Selenium — a cofactor for the glutathione peroxidase that protects the sperm midpiece from oxidative damage.
- Antioxidants — the wider context for the superoxide dismutase, catalase, glutathione and vitamin C findings on this page.
- Endocrinology — the hormone conditions, including hyperprolactinaemia, that should be diagnosed before self-treating.
- Tyrosine — the amino acid the body normally converts into L-DOPA and then dopamine, upstream of everything described here.